Cargando…

Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling

The novel antibody-based immunotherapy in oncology exploits the activation of immune system mediated by immunomodulatory antibodies specific for immune checkpoints. Among them, the programmed death ligand-1 (PD-L1) is of particular interest as it is expressed not only on T-cells, but also on other i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Passariello, Margherita, D’Alise, Anna Morena, Esposito, Annachiara, Vetrei, Cinzia, Froechlich, Guendalina, Scarselli, Elisa, Nicosia, Alfredo, De Lorenzo, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739323/ https://www.ncbi.nlm.nih.gov/pubmed/31511565 http://dx.doi.org/10.1038/s41598-019-49485-3

Ejemplares similares

Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells
por: Passariello, Margherita, et al.
Publicado: (2020)

Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments
por: Vetrei, Cinzia, et al.
Publicado: (2021)

New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC
por: Lembo, Rosa Rapuano, et al.
Publicado: (2022)

Novel Combinations of Human Immunomodulatory mAbs Lacking Cardiotoxic Effects for Therapy of TNBC
por: Vetrei, Cinzia, et al.
Publicado: (2021)

Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries
por: Cembrola, Biancamaria, et al.
Publicado: (2019)

Massive parallel screening of phage libraries for the generation of repertoires of human immunomodulatory monoclonal antibodies
por: Sasso, Emanuele, et al.
Publicado: (2018)

High-Throughput Monoclonal Antibody Discovery from Phage Libraries: Challenging the Current Preclinical Pipeline to Keep the Pace with the Increasing mAb Demand
por: Zambrano, Nicola, et al.
Publicado: (2022)

Generation of a Retargeted Oncolytic Herpes Virus Encoding Adenosine Deaminase for Tumor Adenosine Clearance
por: Gentile, Chiara, et al.
Publicado: (2021)

Replicative conditioning of Herpes simplex type 1 virus by Survivin promoter, combined to ERBB2 retargeting, improves tumour cell-restricted oncolysis
por: Sasso, Emanuele, et al.
Publicado: (2020)

Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2
por: Passariello, Margherita, et al.
Publicado: (2021)

Targeted Nanobubbles of PD-L1 mAb Combined with Doxorubicin as a Synergistic Tumor Repressor in Hepatocarcinoma
por: Chen, Yezi, et al.
Publicado: (2022)

Modulating the tumor microenvironment improves antitumor effect of anti-PD-L1 mAb in breast cancer
por: Li, Xiuying, et al.
Publicado: (2023)

Generation of a Novel Mesothelin-Targeted Oncolytic Herpes Virus and Implemented Strategies for Manufacturing
por: Froechlich, Guendalina, et al.
Publicado: (2021)

On the way of the new strategies aimed to improve the efficacy of PD-1/PD-L1 immune checkpoint blocking mAbs in small cell lung cancer
por: Correale, Pierpaolo, et al.
Publicado: (2020)

Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of Herpes Simplex Oncolytic Virus
por: Froechlich, Guendalina, et al.
Publicado: (2020)

Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy
por: D’Alise, Anna Morena, et al.
Publicado: (2023)

Anti-PD-1 Monoclonal Antibodies (mAbs) Are Superior to Anti-PD-L1 mAbs When Combined with Chemotherapy in First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Network Meta-Analysis
por: Wei, Joe Q., et al.
Publicado: (2023)

Near‐infrared fluorescence‐labeled anti‐PD‐L1‐mAb for tumor imaging in human colorectal cancer xenografted mice
por: Zhang, Mingyu, et al.
Publicado: (2019)

Effects of combined treatment with PD-L1 Ig and CD40L mAb on immune tolerance in the CBA/J × DBA/2 mouse model
por: Li, Guanfei, et al.
Publicado: (2020)

Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma
por: Zhang, Jingzhe, et al.
Publicado: (2019)

Retargeted and Multi-cytokine-Armed Herpes Virus Is a Potent Cancer Endovaccine for Local and Systemic Anti-tumor Treatment
por: De Lucia, Maria, et al.
Publicado: (2020)

The intracellular signalosome of PD-L1 in cancer cells
por: Escors, David, et al.
Publicado: (2018)

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion
por: D'Alise, Anna Morena, et al.
Publicado: (2021)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

A long non-coding SINEUP RNA boosts semi-stable production of fully human monoclonal antibodies in HEK293E cells
por: Sasso, Emanuele, et al.
Publicado: (2018)

Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L(1)Mab-4
por: Yamada, Shinji, et al.
Publicado: (2018)

Study of the interactions of a novel monoclonal antibody, mAb059c, with the hPD-1 receptor
por: Liu, Jingxian, et al.
Publicado: (2019)

Combinatorial therapy with an IL-15 superagonist (ALT-803) and anti-PD-L1 mAb augment T cell mediated anti-tumor immunity in mice
por: Johnson, Christopher B, et al.
Publicado: (2014)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Population pharmacokinetic models of anti-PD-1 mAbs in patients with multiple tumor types: A systematic review
por: Shang, Jingyuan, et al.
Publicado: (2022)

Chloride intracellular channel protein 2: prognostic marker and correlation with PD-1/PD-L1 in breast cancer
por: Xu, Tao, et al.
Publicado: (2020)

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
por: Shen, Xian, et al.
Publicado: (2018)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

PD-L1 methylation restricts PD-L1/PD-1 interactions to control cancer immune surveillance
por: Huang, Changsheng, et al.
Publicado: (2023)

High‐affinity PD‐1 molecules deliver improved interaction with PD‐L1 and PD‐L2
por: Li, Yanyan, et al.
Publicado: (2018)

Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer
por: Jeong, Seri, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ndmh358pen5bad29so8jb535jm